|
|
|
|
|
|
Small molecule drug substance and development remain the backbone of complex therapeutic programs — and knowing where to find the right expertise has never been more critical. That’s why the Outsourced Pharma Capacity Update has evolved into the Outsourced Pharma Capabilities Update (OPCU) — a series designed to go beyond capacity and highlight the real differentiators: the technologies, experience, and specialized capabilities CDMOs bring to your programs.
Across these sessions, you’ll get a clear view into the most critical stages of development — and how the right partners can help reduce cycle times, strengthen quality, and de-risk scale-up for small molecule assets.
Tune in each month to our expanded PARTNER WEEK, organized by capability area, which makes it easier than ever to pinpoint the right CDMO strengths — exactly when you need them.
Recent Sessions Available On-Demand
Large Molecule – 3/10/2026, AM Session
Fill / Finish – 3/10/2026, PM Session
Upcoming OPCU Topics & Times
Small Molecule Drug Product | 4/21/2026, AM Session
Fill/Finish | 4/22/2026, PM Session
Access more on-demand OPCU recordings and upcoming sessions here.
|
|
|
|
|
|
Pace Life Sciences
|
A CDMO leader highlights two decades of growth, showcasing analytical strength, manufacturing, regulatory support, and integrated services that speed drug development.
|
|
Request Information
|
|
Pace® Life Sciences
|
|
|
|
Solvias
|
A biotech leader emphasizes end‑to‑end analytical capabilities from development to commercialization, with expertise in biologics, gene therapies, quality testing, and regulatory solutions.
|
|
Request Information
|
|
Solvias
|
|
|
|
Catalent
|
A biologics analytics leader showcases development, testing, and characterization capabilities, emphasizing quality, regulatory compliance, and integrated support from discovery to commercialization.
|
|
Request Information
|
|
Catalent
|
|
|
|
Recipharm Advanced Bio
|
A lifecycle‑based analytical framework supporting release testing, stability studies, and product characterization to boost regulatory readiness, cut variability, and speed development.
|
|
Request Information
|
|
Recipharm Advanced Bio
|
|
|
|
Minaris
|
Access integrated biosafety testing, viral clearance, product characterization, and GMP analytics that deliver regulatory‑ready data and speed biologic and cell and gene therapy development.
|
|
Request Information
|
|
Minaris
|
|
|
|
|
|
Minaris
|
A global CDMO specializing in cell and gene therapies, offering end-to-end development, manufacturing, and testing services with over 25 years of expertise and personalized client support.
|
|
Request Information
|
|
Minaris
|
|
|
|
Lonza
|
A global CDMO outlines end-to-end capabilities in cell and gene therapy, mRNA, and microbial platforms, emphasizing scalability, innovation, and seamless development through manufacturing.
|
|
Request Information
|
|
Lonza
|
|
|
|
Landmark Bio
|
A translational CDMO approach integrates development, analytics, and GMP manufacturing to streamline cell and gene therapy advancement from early research through clinical production.
|
|
Request Information
|
|
Landmark Bio
|
|
|
|
Comprehensive Cell Solutions
|
An integrated draw‑to‑thaw CDMO model connecting donor sourcing, development, GMP manufacturing, and cryogenic storage to streamline workflows and strengthen quality control.
|
|
Request Information
|
|
Comprehensive Cell Solutions, A Business Unit of NYBC Enterprises
|
|
|
|
ElevateBio
|
Learn how to embed process development expertise early and continuously to eliminate knowledge gaps, reduce risk, and ensure consistent execution from transfer through manufacturing.
|
|
Request Information
|
|
ElevateBio
|
|
|
|
|
